Intersuisse:
Pharmaxis Ltd PXS Thursday, 30 August 2007
Positive Phase III data takes PXS to a $763m Fully Diluted Market Cap
Recommendation Short Term Investor -Take Profits, Long Term Investor - Hold
Pharmaxis reported positive Phase III data on Bronchitol
Pharmaxis reported positive Phase III data on Bronchitol for the management of
mucus deposition in the lungs of bronchiectasis patients.
The value of the company predominantly resides in it lead compound Bronchitol.
The company has Bronchitol in clinical development for the management of
mucus clearance of bronchiectasis patents, as well as cystic fibrosis and chronic
bronchitis.
The company also development and markets a asthma quantification diagnostic.
Aridol for the quantification of asthma has entered the market in Australia and
Europe, as well as completing Phase III trials for US registration.
Positive Bronchiectasis Phase III Clinical Trial
• Data from the 362 subject study demonstrated a highly significant
improvement in quality of life after 12 weeks of treatment with Bronchitol.
The primary endpoint were;
o Positive reports from the St George Respiratory Questionnaire where
patients reported a better health and a higher quality of life.
o Significant difference in mucus clearance at 12 weeks for patients
receiving Bronchitol versus those patients receiving placebo.
• The trial was conducted at 22 hospitals across Australia, New Zealand and
the United Kingdom.
• Secondary endpoint have not yet been assessed, include Bronchiectasis
symptoms (questionnaire), Cough severity (questionnaire), Exercise capacity
(shuttle), Lung function, including gas transfer, changes in Antibiotic use,
Bronchial wall thickening and inflammation and Peripheral airway function.
These data points will be assessed and released later, and will provide the
medical community greater information on the clinical utility of Bronchitol and
assist with the adoption rate of the drug, if the current Phase III data is
accepted by the regulatory authorities.
Recommendation
We previously reported that PXS is trading above the high range of our valuation
by a confidence interval of 75%, assessing the mean valuation of $2.95 per
share as the fair value and recommended Hold for the Long Term investor. The
completion of the Phase III data and a small amount of new equity issued takes
our valuation to $3.79 per share. However, with a 75% level of confidence the
valuation range is high, calculated at high of $4.48 and a low of $2.93 per share
respectively.
At a share price of $4.03 cent per share, we recommend;
• For the Long Term Investor – Hold
• For the Short Term Investor – Take Profits.
Snapshot
Last Price $4.03
Market Cap (A$m) $763m
52 Week High $4.05
52 Week Low $1.84
- Forums
- ASX - By Stock
- SNT
- first broker upgrade: 5.10
first broker upgrade: 5.10, page-15
Featured News
Add SNT (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.1¢ |
Change
0.001(2.50%) |
Mkt cap ! $57.67M |
Open | High | Low | Value | Volume |
4.1¢ | 4.3¢ | 4.0¢ | $18.91K | 463.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 191034 | 4.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.3¢ | 302037 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 191034 | 0.041 |
3 | 450000 | 0.040 |
1 | 750000 | 0.039 |
1 | 52631 | 0.038 |
3 | 620000 | 0.037 |
Price($) | Vol. | No. |
---|---|---|
0.043 | 302037 | 4 |
0.044 | 531746 | 3 |
0.045 | 968252 | 3 |
0.046 | 1100000 | 2 |
0.047 | 20000 | 1 |
Last trade - 14.10pm 10/10/2024 (20 minute delay) ? |
Featured News
SNT (ASX) Chart |
The Watchlist
EL8
ELEVATE URANIUM LTD
Murray Hill, MD & CEO
Murray Hill
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online